Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study
| العنوان: | Multiparametric magnetic resonance imaging can exclude prostate cancer progression in patients on active surveillance: a retrospective cohort study |
|---|---|
| المؤلفون: | F Mones, Lars Schimmöller, D. Mally, Christian Arsov, Michael Quentin, Antonio C. Westphalen, Gerald Antoch, Andreas Hiester, Peter Albers, T Ullrich |
| المصدر: | European Radiology |
| بيانات النشر: | Springer Berlin Heidelberg, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Image-Guided Biopsy, Male, medicine.medical_specialty, 030232 urology & nephrology, Assessment, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Prostate, Predictive Value of Tests, Biopsy, medicine, Clinical endpoint, Humans, Radiology, Nuclear Medicine and imaging, Multiparametric Magnetic Resonance Imaging, Watchful Waiting, risk, Aged, Retrospective Studies, Ultrasonography, medicine.diagnostic_test, business.industry, Cancer, Prostatic Neoplasms, Magnetic resonance imaging, Retrospective cohort study, Urogenital, General Medicine, Imaging-guided biopsy, Middle Aged, Prostate-Specific Antigen, medicine.disease, Early diagnosis, Magnetic Resonance Imaging, medicine.anatomical_structure, Tumor progression, 030220 oncology & carcinogenesis, Disease Progression, Radiology, Neoplasm Grading, business |
| الوصف: | Objectives To assess the ability of multiparametric MRI (mp-MRI) of the prostate to exclude prostate cancer (PCa) progression during monitoring patients on active surveillance (AS). Methods One hundred forty-seven consecutive patients on AS with mp-MRI (T2WI, DWI, DCE-MRI) at 3T were initially enrolled. Fifty-five received follow-up mp-MRI after a minimum interval of 12 months and subsequent targeted MR/US fusion-guided biopsy (FUS-GB) plus concurrent systematic transrectal ultrasound-guided (TRUS-GB) biopsy as reference standard. Primary endpoint was the negative predictive value (NPV) of the follow-up mp-MRI to exclude histopathologic tumor progression using PRECISE recommendations. Secondary endpoints were the positive predictive value (PPV), sensitivity, specificity, Gleason score (GS) upgrades, and comparison of biopsy method. Results Of 55 patients, 29 (53%) had a GS upgrade on re-biopsy. All 29 patients showed a tumor progression on follow-up mp-MRI. Fifteen of 55 patients (27%) displayed signs of tumor progression, but had stable GS on re-biopsy. None of the 11 patients (20%) without signs of progression on follow-up mp-MRI had a GS upgrade on re-biopsy. The NPV was 100%, PPV was 66%, sensitivity was 100%, and specificity 42%. FUS-GB resulted in GS upgrade significantly more often (n = 28; 51%) compared with TRUS-GB (n = 12; 22%; p < 0.001). Conclusions (Follow-up) Mp-MRI can reliably exclude PCa progression in patients on AS. Standard serial re-biopsies might be waived if follow-up mp-MRIs are stable. Over 60% of patients with signs of tumor progression on mp-MRI during AS had a GS upgrade on re-biopsy. Targeted re-biopsies should be performed if cancer progression or higher-grade PCa is suspected on mp-MRI. Key Points • None of the patients with unsuspicious mp-MRI had a GS upgrade in re-biopsy and mp-MRI might replace serial biopsies in these cases • More than 60% of patients with mp-MRI signs of tumor progression had subsequent Gleason score (GS) upgrades • Targeted re-biopsies should be performed in case of higher GS cancer suspicion on mp-MRI |
| اللغة: | English |
| تدمد: | 1432-1084 0938-7994 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfbb427563344077a06d8a859f6ad981Test http://europepmc.org/articles/PMC7553894Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....dfbb427563344077a06d8a859f6ad981 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14321084 09387994 |
|---|